Finance

Lists
ALPMY:OTCMKTS
Astellas Pharma ADR Representing 1 Ord Shs
14,35 US$
+1,06%
(+0,15) 1D
9 ოქტ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALPMY...
Open
14,23 US$
High
14,37 US$
Low
14,17 US$
Mkt. cap
4,07 ტრლ.
Avg. vol.
100,36 ათ.
Volume
122,21 ათ.
52-wk high
17,35 US$
52-wk low
10,03 US$
Beta
0,13
Shares outstanding
1,81 მლრდ.
No. of employees
14 ათ.
Open
14,23 US$
High
14,37 US$
Low
14,17 US$
Mkt. cap
4,07 ტრლ.
Avg. vol.
100,36 ათ.
Volume
122,21 ათ.
52-wk high
17,35 US$
52-wk low
10,03 US$
Beta
0,13
Shares outstanding
1,81 მლრდ.
No. of employees
14 ათ.
News stories
From web sources and news partners
Profile
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Astellas is a member of the Mitsubishi UFJ Financial Group keiretsu. Wikipedia
About Astellas Pharma ADR Representing 1 Ord Shs
CEOნაოკი ოკამურა
Employees14,1 ათ.
Founded1 აპრ. 2005
Headquartersჩუო, ტოკიო, იაპონია
SectorPharmaceutical industry
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
524,32 მლრ.
554,57 მლრ.
537,92 მლრ.
640,91 მლრ.
Cost of goods sold
105,53 მლრ.
104,03 მლრ.
93,67 მლრდ.
122,70 მლრ.
Cost of revenue
105,53 მლრ.
104,03 მლრ.
93,67 მლრდ.
122,70 მლრ.
Research and development expenses
71,59 მლრდ.
85,77 მლრდ.
95,94 მლრდ.
81,73 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
206,84 მლრ.
228,24 მლრ.
234,70 მლრ.
215,07 მლრ.
Operating expense
325,88 მლრ.
358,98 მლრ.
336,48 მლრ.
332,86 მლრ.
Total operating expenses
431,41 მლრ.
463,01 მლრ.
430,14 მლრ.
455,56 მლრ.
Operating income
92,91 მლრდ.
91,55 მლრდ.
107,78 მლრ.
185,35 მლრ.
Other non operating income
-
1,50 მლნ.
-241,00 მლნ.
1,00 მლნ.
EBT including unusual items
104,19 მლრ.
90,99 მლრდ.
48,02 მლრდ.
186,51 მლრ.
EBT excluding unusual items
92,38 მლრდ.
90,82 მლრდ.
113,57 მლრ.
186,51 მლრ.
Income tax expense
24,98 მლრდ.
19,02 მლრდ.
4,41 მლრდ.
44,76 მლრდ.
Effective tax rate
23,97%
20,90%
9,18%
24,00%
Other operating expenses
14,73 მლრდ.
9,72 მლრდ.
-29,93 მლრდ.
388,00 მლნ.
Net income
79,21 მლრდ.
71,95 მლრდ.
43,52 მლრდ.
141,83 მლრ.
Net profit margin
15,11%
12,97%
8,09%
22,13%
Earnings per share
-
-
-
-
Interest and investment income
2,15 მლრდ.
2,10 მლრდ.
1,29 მლრდ.
5,13 მლრდ.
Interest expense
-2,69 მლრდ.
-2,74 მლრდ.
-
-3,12 მლრდ.
Net interest expenses
-541,00 მლნ.
-637,00 მლნ.
1,29 მლრდ.
2,01 მლრდ.
Depreciation and amortization charges
-32,77 მლრდ.
-
35,76 მლრდ.
-
EBITDA
140,20 მლრ.
141,30 მლრ.
158,14 მლრ.
235,24 მლრ.
Gain or loss from assets sale
16,40 მლრდ.
-
31,51 მლრდ.
-
AI content may include mistakes. Learn more
Google აპები